COPD is not officially classified as an autoimmune disease, but it has a surprisingly strong autoimmune component that researchers are still working to fully understand. The traditional view of COPD as simple damage from smoking or pollution is giving way to a more complex picture: one where the immune system turns against the lungs and actively drives disease progression, even after a person stops smoking.
Why COPD Looks Like an Autoimmune Disease
In a classic autoimmune disease like rheumatoid arthritis or lupus, the immune system mistakenly attacks the body’s own tissues. COPD shares several hallmarks of this process. About 34% of people with stable COPD have abnormally high levels of antinuclear antibodies (a standard marker of autoimmune activity), compared to roughly 3% of healthy controls. That’s an 11-fold difference. Similarly, 26% of COPD patients show elevated anti-tissue antibodies, about four times the rate seen in healthy people. These are the same types of immune markers that doctors use to diagnose recognized autoimmune conditions.
The antibody findings go deeper than general markers. Researchers have found that 97% of COPD plasma samples contained antibodies that targeted the patients’ own proteins, compared to 0% of never-smoked controls. Antibodies specifically directed against lung epithelial cells (the cells lining the airways) were found in all 12 COPD patients tested in one study, versus only 3 of 12 healthy controls. These self-targeting antibodies aren’t just bystanders. When researchers exposed lung cells to plasma from COPD patients, the destruction of those cells increased by 46% compared to plasma from healthy individuals.
How Smoking Triggers the Immune Response
The connection between smoking and autoimmunity in COPD starts with tissue damage. Cigarette smoke contains hundreds of toxic substances that kill airway cells outright. When those cells die, they release proteins that are normally hidden inside the cell, exposing them to the immune system for the first time. The immune system doesn’t recognize these newly exposed proteins as “self” and mounts an attack.
Smoking also chemically alters proteins in the lungs through a process called post-translational modification. Smoke triggers changes like citrullination, carbonylation, and carbamylation, which essentially disguise the body’s own proteins so the immune system treats them as foreign invaders. The lung’s own immune cells, including neutrophils and macrophages, ramp up the enzymes that create these modified proteins, generating a cycle of damage and immune activation right inside the lung tissue. This is the same basic mechanism that drives rheumatoid arthritis, which shares smoking as a major risk factor and overlaps with COPD more often than many clinicians recognize.
The Immune Cells Driving Progression
Two types of immune cells play central roles in COPD’s autoimmune-like behavior. Th1 and Th17 cells, both associated with autoimmune diseases, are found in elevated numbers in the lungs of people with emphysema. When researchers exposed immune cells from COPD patients to fragments of elastin (a structural protein in the lung that breaks down during emphysema), those cells differentiated into both Th1 and Th17 subtypes. This means the immune system is specifically reacting to the lung’s own structural components.
Th17 cells produce a signaling molecule called IL-17, which recruits waves of inflammatory cells into the lungs and activates tissue-resident immune cells. In animal studies, mice chronically exposed to cigarette smoke had significantly higher numbers of IL-17-producing cells in their lungs. This creates a self-sustaining loop: smoke damages the lung, the immune system reacts to the damage, and the immune reaction causes more damage.
As COPD advances, immune cells organize into structures called lymphoid follicles within the lung tissue. These are essentially miniature immune command centers, similar to what’s seen in the joints of people with rheumatoid arthritis or the thyroid glands of people with Hashimoto’s disease. Their presence suggests a localized, organized autoimmune response rather than random inflammation.
Why It Matters for Disease Progression
The autoimmune component of COPD helps explain one of the disease’s most frustrating features: it keeps getting worse even after a person quits smoking. If COPD were purely a response to inhaled irritants, removing the irritant should slow or stop the decline. Instead, many former smokers continue to lose lung function for years. The autoimmune theory offers an explanation. Once the immune system has been trained to attack lung tissue, that response becomes self-perpetuating, independent of the original trigger.
There’s also evidence that specific autoantibodies are linked to specific outcomes. COPD patients with antibodies targeting a particular 130-kilodalton protein had significantly lower body mass, with an average BMI of 23.2 compared to 29.5 in those without the antibody. This suggests that some autoimmune responses in COPD may drive systemic effects like the muscle wasting and weight loss that mark severe disease, not just lung destruction. Immune complexes (clumps of antibodies bound to their targets) were found in the lung tissue of all six COPD patients examined in one study, compared to none of six healthy lungs.
Where Medical Guidelines Stand
Despite the growing evidence, COPD is still officially categorized as a chronic inflammatory lung disease, not an autoimmune disease. The latest GOLD report (the international guideline that defines COPD management) focuses on inflammation-driven treatment, including a new biologic therapy that blocks specific immune signaling molecules. This biologic, which targets the IL-4 and IL-13 pathway, is recommended for patients who keep having flare-ups despite maximum standard treatment and who have elevated eosinophil counts.
Researchers increasingly describe COPD as part of a “continuum of immune-mediated diseases,” where autoimmunity plays a key role in progression alongside the better-understood inflammatory pathways. The genetic basis of emphysema also fits this framing: susceptibility patterns resemble those of recognized autoimmune disorders, with multiple genes contributing small effects rather than a single gene causing the disease. This heritable pattern is one more piece of evidence that COPD’s immune dysfunction runs deeper than a straightforward reaction to smoke.
What This Means in Practice
For people living with COPD, the autoimmune dimension has a few practical implications. First, it validates the experience of continued decline after quitting smoking. Your lungs aren’t just scarred from past damage; your immune system may be actively contributing to ongoing deterioration. Second, it connects COPD to other autoimmune and inflammatory conditions. If you have COPD alongside rheumatoid arthritis or another autoimmune disease, the overlap is likely not coincidental. These conditions share inflammatory pathways, genetic susceptibility, and environmental triggers.
The autoimmune understanding is also opening new treatment directions. The approval of biologic therapy for certain COPD patients represents a shift toward targeting specific immune pathways rather than broadly suppressing inflammation with steroids. As the field continues to map which immune responses drive which aspects of the disease, treatments are likely to become more targeted, potentially borrowing approaches that have already proven effective in autoimmune conditions.